Analysts’ Weekly Ratings Changes for Hologic (HOLX)

Several analysts have recently updated their ratings and price targets for Hologic (NASDAQ: HOLX):

• 12/13/2024 – Hologic is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.
• 12/10/2024 – Hologic was upgraded by analysts at BNP Paribas to a “strong-buy” rating.
• 12/10/2024 – Hologic is now covered by analysts at Jefferies Financial Group Inc.. They set a “hold” rating and a $85.00 price target on the stock.
• 12/10/2024 – Hologic had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $90.00 price target on the stock.
• 11/14/2024 – Hologic was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 11/6/2024 – Hologic was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/5/2024 – Hologic had its price target raised by analysts at Royal Bank of Canada from $86.00 to $89.00. They now have a “sector perform” rating on the stock.
• 11/5/2024 – Hologic had its price target raised by analysts at JPMorgan Chase & Co. from $92.00 to $94.00. They now have an “overweight” rating on the stock.
• 11/5/2024 – Hologic had its price target lowered by analysts at Mizuho from $90.00 to $87.00. They now have an “outperform” rating on the stock.
• 11/5/2024 – Hologic had its price target raised by analysts at Raymond James from $93.00 to $95.00. They now have an “outperform” rating on the stock.
• 11/5/2024 – Hologic had its price target raised by analysts at UBS Group AG from $84.00 to $90.00. They now have a “neutral” rating on the stock.

Hologic Trading Down 1.6 %

Shares of Hologic stock opened at $72.44 on Tuesday. The company has a market capitalization of $16.44 billion, a P/E ratio of 21.75, a price-to-earnings-growth ratio of 2.38 and a beta of 0.96. The stock has a fifty day simple moving average of $79.17 and a 200 day simple moving average of $78.64. Hologic, Inc. has a 12-month low of $70.24 and a 12-month high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same quarter in the prior year, the company posted $0.89 earnings per share. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Transactions at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.75% of the company’s stock.

Institutional Trading of Hologic

Several hedge funds have recently added to or reduced their stakes in the stock. FMR LLC increased its stake in shares of Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares during the last quarter. Black Creek Investment Management Inc. raised its stake in shares of Hologic by 60.9% in the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after buying an additional 885,524 shares during the period. Mackenzie Financial Corp lifted its position in shares of Hologic by 1,023.3% during the 2nd quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock valued at $66,506,000 after buying an additional 815,960 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Hologic during the 2nd quarter worth $39,427,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Hologic by 21.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock worth $188,243,000 after acquiring an additional 450,190 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.